LON:SBTX

SkinBioTherapeutics Interim Earnings Report

SkinBioTherapeutics logo
GBX 11 0.00 (0.00%)
As of 06/24/2026 06:19 AM Eastern

SkinBioTherapeutics EPS Results

Actual EPS
-GBX 0.46
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

SkinBioTherapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

SkinBioTherapeutics Announcement Details

Quarter
Interim
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

SkinBioTherapeutics Earnings Headlines

Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now.tc pixel
AIM Market Roundup: IQE, System1, SkinBioTherapeutics
See More SkinBioTherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like SkinBioTherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on SkinBioTherapeutics and other key companies, straight to your email.

About SkinBioTherapeutics

SkinBioTherapeutics (LON:SBTX), a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has an agreement with Croda Plc; and operates two research programmes with the University of Manchester, an oral programme and an inflammation study. It serves cosmetic skincare, food supplements, medical skin care, infection control, and pharmaceutical skincare markets. The company was formerly known as Skinbiotix Ltd and changed its name to SkinBioTherapeutics plc in December 2016. SkinBioTherapeutics plc was incorporated in 2015 and is based in Newcastle upon Tyne, the United Kingdom.

View SkinBioTherapeutics Profile